Genscript Biotech Corporation Net Assets
Genscript Biotech Corporation net assets. Based on the latest financial reports, Genscript Biotech Corporation (G51) has net assets worth €3.96 Billion EUR (≈ $4.64 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.85 Billion ≈ $5.67 Billion USD) and total liabilities (€888.59 Million ≈ $1.04 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Genscript Biotech Corporation to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.96 Billion |
| % of Total Assets | 81.69% |
| Annual Growth Rate | 40.66% |
| 5-Year Change | 262.75% |
| 10-Year Change | N/A |
| Growth Volatility | 51.03 |
Net Assets of Genscript Biotech Corporation (2016–2025)
Net assets of Genscript Biotech Corporation from 2016 to 2025. This chart illustrates how Genscript Biotech Corporation's net assets have evolved over time, based on quarterly financial data. See Genscript Biotech Corporation (G51) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Genscript Biotech Corporation (2016–2025)
The table below shows the annual net assets of Genscript Biotech Corporation from 2016 to 2025. For live market cap and overall valuation, see market value of Genscript Biotech Corporation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €3.96 Billion ≈ $4.64 Billion |
-8.30% |
| 2024-12-31 | €4.32 Billion ≈ $5.05 Billion |
+111.48% |
| 2023-12-31 | €2.04 Billion ≈ $2.39 Billion |
+50.03% |
| 2022-12-31 | €1.36 Billion ≈ $1.59 Billion |
+24.68% |
| 2021-12-31 | €1.09 Billion ≈ $1.28 Billion |
+34.01% |
| 2020-12-31 | €815.59 Million ≈ $953.51 Million |
+119.07% |
| 2019-12-31 | €372.30 Million ≈ $435.26 Million |
-24.53% |
| 2018-12-31 | €493.30 Million ≈ $576.72 Million |
+116.06% |
| 2017-12-31 | €228.32 Million ≈ $266.93 Million |
+24.07% |
| 2016-12-31 | €184.02 Million ≈ $215.14 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genscript Biotech Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2136.2% over the analyzed period, indicating profitable operations and earnings retention.
Genscript Biotech Corporation Net Assets Breakdown (December 2025)
Genscript Biotech Corporation net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.82 Billion | 45.91% |
| Other Components | €2.14 Billion | 54.09% |
| Total Equity | €3.96 Billion | 100.00% |
Genscript Biotech Corporation Competitors by Market Cap
The table below lists competitors of Genscript Biotech Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Impinj Inc
NASDAQ:PI
|
$3.36 Billion |
|
Sino-American Silicon Products
TWO:5483
|
$3.37 Billion |
|
National Storage Affiliates Trust
NYSE:NSA
|
$3.37 Billion |
|
Jason Furniture(Hangzhou)
SHG:603816
|
$3.37 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
$3.36 Billion |
|
Suzhou Everbright Photonics Co. Ltd. A
SHG:688048
|
$3.36 Billion |
|
Skeena Resources Ltd
TO:SKE
|
$3.36 Billion |
|
Jiangsu Changshu Rural Commercial Bank Co Ltd
SHG:601128
|
$3.36 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genscript Biotech Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,321,172,000 to 3,959,331,000, a change of -361,841,000 (-8.4%).
- Net loss of 532,830,000 reduced equity.
- Share repurchases of 225,142,000 reduced equity.
- New share issuances of 6,019,000 increased equity.
- Other factors increased equity by 390,112,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-532.83 Million | -13.46% |
| Share Repurchases | €225.14 Million | -5.69% |
| Share Issuances | €6.02 Million | +0.15% |
| Other Changes | €390.11 Million | +9.85% |
| Total Change | €- | -8.37% |
Book Value vs Market Value Analysis
This analysis compares Genscript Biotech Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 31.52x to 2.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.13 | €3.96 | x |
| 2018-12-31 | €0.26 | €3.96 | x |
| 2019-12-31 | €0.20 | €3.96 | x |
| 2020-12-31 | €0.46 | €3.96 | x |
| 2021-12-31 | €0.42 | €3.96 | x |
| 2022-12-31 | €0.48 | €3.96 | x |
| 2023-12-31 | €0.66 | €3.96 | x |
| 2024-12-31 | €2.02 | €3.96 | x |
| 2025-12-31 | €1.81 | €3.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genscript Biotech Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -55.53%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.23x
- Recent ROE (-13.46%) is below the historical average (-3.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 14.73% | 22.81% | 0.51x | 1.27x | €8.41 Million |
| 2017 | 11.99% | 17.11% | 0.30x | 2.32x | €4.34 Million |
| 2018 | 4.43% | 9.18% | 0.25x | 1.92x | €-26.65 Million |
| 2019 | -25.32% | -35.45% | 0.31x | 2.32x | €-135.19 Million |
| 2020 | -22.73% | -52.51% | 0.27x | 1.61x | €-295.12 Million |
| 2021 | -39.54% | -68.13% | 0.23x | 2.54x | €-435.84 Million |
| 2022 | -22.45% | -36.26% | 0.25x | 2.52x | €-327.91 Million |
| 2023 | -6.86% | -17.03% | 0.17x | 2.44x | €-234.58 Million |
| 2024 | 68.54% | 498.22% | 0.11x | 1.22x | €2.53 Billion |
| 2025 | -13.46% | -55.53% | 0.20x | 1.23x | €-928.76 Million |
Industry Comparison
This section compares Genscript Biotech Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $380,407,590
- Average return on equity (ROE) among peers: -34.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genscript Biotech Corporation (G51) | €3.96 Billion | 14.73% | 0.22x | $3.36 Billion |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $-1.58 Million | 0.00% | 0.00x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $243.06 Million | -74.97% | 0.23x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $144.67 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $696.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Scien… Read more